MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 05.03.2026
Adial Pharmaceuticals Operativer Cashflow 2011-2026 | ADIL
Operativer Cashflow Jährlich Adial Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.49 M | -6.92 M | -6.81 M | -11.2 M | -11.9 M | -7.63 M | -6.34 M | -2.5 M | -495 K | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -495 K | -11.9 M | -6.7 M |
Operativer Cashflow Vierteljährlich Adial Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -1.59 M | - | - | - | - | - | - | -2.3 M | - | -9.44 M | -6.03 M | -2.5 M | - | -9.58 M | -6.05 M | -2.84 M | - | -5.02 M | -2.81 M | -1.83 M | - | -4.59 M | -2.86 M | -1.72 M | - | -1.39 M | -403 K | -214 K | - | -373 K | -236 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -214 K | -9.58 M | -3.25 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 3.88 | - | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 215.54 | - | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 86.81 | - | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 19.23 | - | $ 899 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Cara Therapeutics
CARA
|
-92.1 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Collegium Pharmaceutical
COLL
|
329 M | $ 33.23 | - | $ 1.05 B | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 8.18 | - | $ 109 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-14.1 M | $ 0.71 | - | $ 8.13 M | Israel |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.32 | - | $ 337 M | Britain |
 |
CytomX Therapeutics
CTMX
|
-75.6 M | $ 4.24 | - | $ 585 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-7.99 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.65 | - | $ 16.6 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
66.5 M | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
-7.87 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Eton Pharmaceuticals
ETON
|
10.5 M | $ 22.97 | - | $ 618 M | USA |
 |
Exelixis
EXEL
|
884 M | $ 41.57 | - | $ 11.3 B | USA |
 |
Fortress Biotech
FBIO
|
-80.2 M | $ 2.92 | - | $ 60.7 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-39.6 M | $ 4.31 | - | $ 826 M | Canada |
 |
Homology Medicines
FIXX
|
-33.5 M | - | 0.77 % | $ 53.4 M | USA |